Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow: Drug Appears Safe and Well Tolerated.
- In November 2021 , Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. - No government agency has informed Cassava Sciences that it has found any evidence of research
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced
- Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern - AUSTIN, Texas , April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the
– All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5 th , 9am ET – AUSTIN, Texas , April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions via Email – – Fireside Chat Will Be Open to The Public via Webcast – AUSTIN, Texas , March 30, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
AUSTIN, Texas , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.
AUSTIN, Texas , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney
New website ( www.Rethink-ALZ.com ) is intended to increase visibility and information for potential study participants. Rethink-ALZ.com connects patients with nearest participating clinical site. Phase 3 efficacy studies now in over 25 clinical sites across the country. AUSTIN, Texas , Dec.
Editor-in- Chief States : “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.” Clearance Is From A Neutral Party Who Is Expert In The Field AUSTIN, Texas , Dec.
